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E-mail address: ssukhano@tulane.edu (S. SukhanoWe have shown previously that insulin like-growth factor I (IGF-1) suppressed atherosclerosis in
Apoe/ mice and activated endothelial nitric oxide (NO) synthase. To determine whether IGF-1-
induced atheroprotection depends on NO, IGF-1- or saline-infused mice were treated with L-NAME,
the pan-NO synthase inhibitor or with D-NAME (control). IGF-1 reduced atherosclerosis in both the
D-NAME and L-NAME groups suggesting that IGF-1’s anti-atherogenic effect was NO-independent.
IGF-1 increased plaque smooth muscle cells, suppressed cell apoptosis and downregulated lipopro-
tein lipase and these effects were also NO-independent. On the contrary, IGF-1 decreased oxidative
stress and suppressed TNF-a levels and these effects were blocked by L-NAME. Thus IGF-1’s anti-oxi-
dant effect is dependent on its ability to increase NO but is distinct from its anti-atherosclerotic
effect which is NO-independent.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction creases atherosclerosis in Apoe/mice [6] and chronic administra-Atherosclerosis is the principal underlying cause of most cardio-
vascular disease-related deaths, the leading cause of mortality in
the USA [1]. Long considered to result from progressive vascular li-
pid accumulation, atherosclerosis is now recognized as a chronic
inﬂammatory disease [2]. Insulin-like growth factor-1 (IGF-1) is
an endocrine and autocrine/paracrine growth factor that is the pri-
mary mediator of the effect of growth hormone on developmental
growth [3]. We have demonstrated that IGF-1 suppresses athero-
sclerosis in Apoe/ mice fed with high fat (Western-type) diet for
12 weeks. This effect was associated with a reduction in vascular
and systemic oxidative stress, an increase in circulating nitric oxide
(NO) bioavailability and vascular endothelial nitric oxide synthase
(eNOS/NOS3) expression, the main NO-producing enzyme in the
vascular wall [4]. NO exerts an array of potentially atheroprotective
effects on the vasculature, including suppression of cell apoptosis,
inﬂammation and oxidative stress [5]. A null mutation for eNOS in-lf of the Federation of European Bi
nthase; IGF-1, insulin like-
cells; LPL, lipoprotein lipase;
NAME, Nx-Nitro-D-arginine
ate 13-acetate; TNF-a, tumor
x, nitrate/nitrite
y Heart & Vascular Institute,
SA. Fax: +1 504 988 4237.
v).tion of L-arginine (a NOS substrate for NO synthesis) reduces the
extent of atherosclerosis [7]. To determine whether nitric oxide
mediates IGF-1-induced antioxidant and/or anti-atherogenic
effects, Apoe/ mice were infused with IGF-1 or saline (control)
in the presence of the pan-NOS inhibitor L-arginine methyl ester
hydrochloride (L-NAME) [8] or the inactive enantiomer, Nx-Nitro-
D-arginine methyl ester hydrochloride (D-NAME) and mice were
fed with a Western diet for 12 weeks. Our ﬁndings indicate that
IGF-1’s anti-oxidant effect was partially blunted by L-NAME; how-
ever IGF-1-induced reduction in atherosclerosis and in plaque apop-
tosis were NO-independent.
2. Materials and methods
2.1. Animals
All animal experiments were performed according to protocols
approved by the Institutional Committee for Use and Care of
Laboratory Animals. Apoe/ mice (C57BL/6, 8 weeks of age, Jack-
son Lab) were infused with saline or IGF-1 (1.5 mg/kg/day) using
osmotic mini-pumps (ALZET, Cupertino, CA). IGF-1 dose and drug
administration protocol were selected based on our previous report
[9]. Mice were fed a high-cholesterol pro-atherogenic diet (Wes-
tern-type diet, 42% of calories from fat) from Harlan-Teklad (TD
88137) for 12 weeks. Diet formula and nutrient information areochemical Societies.
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Nx-Nitro-L-arginine methyl ester hydrochloride (L-NAME, 1 mg/
ml, Sigma–Aldrich, St. Louis, MO) or Nx-Nitro-D-arginine methyl
ester hydrochloride (D-NAME, 1 mg/ml, Sigma–Aldrich) was added
to the drinking water and water was replaced every other day. Mice
were housed individually and maintained on a 12-h light-dark
cycle.
2.2. Cell culture
HumanTHP-1mononuclear cellswere purchased fromATCC and
were cultured in RPMI1640media (ATCC) as permanufacturer’s rec-
ommendations. Phorbol 12-myristate 13-acetate (PMA, 100 ng/ml,
Sigma–Aldrich) was added to THP-1monocytes for 48 h to promote
cell differentiation into macrophages. PMA-treated cells were con-
sidered to be macrophages based on typical macrophage-like phe-
notype and immunopositivity for CD36 and CD16. THP-1
macrophages were treated with 50 ng/ml human recombinant
IGF-1 (Tersica) for 16 h and gene expression analysiswas performed
by quantitative real-time RT–PCR with b-actin, tumor necrosis fac-
tor a (TNF-a) and lipoprotein lipase (LPL) sequence-speciﬁc primer
pairs (Qiagen/SABiosciences).
2.3. Atherosclerosis burden quantiﬁcation
Atherosclerosis burden was quantiﬁed by measuring the sur-
face area of Oil Red O–positive lesions on en face preparations of
whole aortas as previously described [9]. Additionally, serial sec-
tions (6 lm) were taken throughout the entire aortic valve area
as per Paigen et al. [10] and stained with H&E for quantitation of
plaque cross-sectional area as previously described [9].
2.4. Immunohistochemistry (IHC)
Serial aortic valveparafﬁn-embeddedcross sectionswere stained
for a-smoothmuscle actin (a-SMA), 8-oxo-D-guanosine (8-oxo-dG)
and N-tyrosine. Antibodies were from Chemicon/Millipore (mouse
anti-a-SMA antibody and rabbit anti-N-tyrosine antibody) and
Abcam (mouse anti-8-oxo-dG antibody). 40,6-diamidino-2-phenyl-
indole (DAPI) was from Invitrogen. Sections were also stained with
Gomori’s Trichrome stain to visualize collagen (Richard-Allan Scien-
tiﬁc, Kalamazoo,MI). Antibody speciﬁcitywas veriﬁed by staining of
serial sections with ‘‘normal’’ IgG (obtained from an unimmunized
animal of the same species as primary antibody) and/or by staining
with blocked primary antibody. Section stained with ‘‘normal’’ rab-
bit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) or with anti-N-
tyrosine antibody blocked by incubation with 3-nitro-L-tyrosine
(Sigma–Aldrich, 200 lM, 1 h) served as the negative control for
anti-N-tyrosine IHC (Supplementary Fig. 1A). Normal mouse IgG
was the control for anti-a-SMA and anti-8-oxo-dG antibody (Sup-
plementary Fig. 1B).
2.5. Quantiﬁcation of cell apoptosis
Cell apoptosis was quantiﬁed in parafﬁn-embedded aortic valve
cross sections with the Apoptosis TUNEL detection kit from Roche
as per manufacturer’s instructions. To identify apoptotic smooth
muscle cells (SMC) in the atherosclerotic plaque, TUNEL-stained
sections were co-stained with a-SMA antibody (1:1000) followed
by incubation with biotinylated secondary antibody and streptavi-
din–Alexa 594 complex (Invitrogen). Sections were mounted with
DAPI-contained mounting media (Vector Laboratories Inc.). Total
cell apoptosis was deﬁned as TUNEL-positive cell number per
1000 plaque cells and SMC apoptosis was measured as the number
of a-SMA/TUNEL-double positive cells per 1000 a-SMA-positive
cells.2.6. Gene expression analysis
Gene expression proﬁling of mouse atherosclerotic aortas was
performed in a 96-well plate with an Atherosclerosis RT2 Proﬁler
PCRArray system (Qiagen/SABiosciences, Frederick,MD). Real-time
PCR was performed using a 40 cycle two-step PCR protocol in the
iCycler IQ real-time detection system (Bio-Rad, Hercules, CA). For
RT array statistical analysis the cycle threshold value (Ct) of each
gene-of-interest was normalized to ﬁve housekeeping genes which
are included in this commercially availablekit. ThePvalueswerecal-
culated based on a Student’s t-test of the replicate 2DCt values for
each gene in the group of IGF-1 infusedmice vs. saline-infusedmice
(control) treated either with L-NAME or D-NAME using the Superar-
ray Analysis software provided by the manufacturer. In addition to
RT array-based gene expression analysis, we measured TNF-a and
LPL mRNA levels in mouse atherosclerotic aortas and in human
THP-1macrophages using speciﬁcmouse RT primer pairs formouse
TNF-a (cat# PPM03113F), LPL (cat# PPM04353E) and for human
TNF-a (cat# PPH00341E) and LPL (cat# PPH00023B) from Qiagen
using standard real time PCR protocol as described previously [9].
2.7. Biochemical assays
IGF-1 and TNF-a ELISA kits were obtained from Diagnostic
Systems Laboratories (Webster, TX). Total cholesterol levels
were measured using a commercially available kit (Cholesterol/
Cholesteryl Ester Quantitation Kit, BioVision, Mountain View,
CA). Blood glucose levels were determined using OneTouchR test
strips (LifeScan).
2.8. Lipoprotein analysis
Serum lipoproteins were fractionated using an FPLC system
(Pharmacia) with a Superose 6 column. Fifty 0.5-ml fractions were
collected at a rate of 0.5 ml/min and analyzed for cholesterol and
triglyceride concentrations. Individual lipoprotein fractions (VLDL,
IDL/LDL, and HDL) were identiﬁed by performing Western blot
analysis on ApoB and ApoA-I in each fraction and by testing puri-
ﬁed lipoproteins (EMD Biosciences) for their elution proﬁles in
the same running condition.
2.9. Urinary nitrate/nitrite (NOx) levels
Twenty-four urine was collected from mice after 4, 8 and
12 weeks of infusion with saline or IGF-1 and treatment with
L-NAME or D-NAME. NOx levels were measured with the Griess
method. Brieﬂy, the urine was ﬁltered, diluted with assay buffer
and mixed with cofactor and nitrate reductase (NOx colorimetric
assay kit, Cayman Chemical Co.). After conversion of nitrate to ni-
trite, total nitrite was measured by reaction with Griess reagent
(sulfanilamide and naphthalene-ethylene diamine dihydrochlo-
ride). Amounts of nitrite in the urine were estimated by a standard
curve obtained from enzymatic conversion of NaNO3 to nitrite and
normalized to animal body weight.
2.10. Statistical analysis
Four groups of mice have been used for this study (n = 12 per
group) and the entire experiment was repeated two times. Data in
graphs is shown as mean ± S.E.M. The experiment with cultured
macrophages (n = 4 per group) was repeated four times. The IGF-1
effect, L-NAME treatment effect and potential interaction between
these effects were analyzed by repeated measures analysis of vari-
ance (two-way ANOVA) using GraphPad Prism 4.0 software (Graph-
Pad Software, Inc.) and P values of less than 0.05 were considered
statistically signiﬁcant. If interactions between the IGF-1 and
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Bonferroni posttest was applied. Analysis for presence of potential
outliers in the data-set was performed with Grubb’s test.
3. Results
3.1. L-NAME reduced nitric oxide bioavailability and increased blood
pressure
Apoe/ mice infused with human recombinant IGF-1 had a
60 ± 9% (D-NAME group) or 74 ± 12% increase (L-NAME group) in to-
tal (mouse plus human) serum IGF-1 levels compared to saline-in-
fused controls (P < 0.001) (Fig. 1A). Mouse (endogenous) IGF-1
levels were reduced in IGF-1-infused mice compared to saline con-
trols (D-NAME group, ng/ml, IGF-1: 206.0 ± 28.6 vs. Saline:
280.7 ± 22.6, P < 0.05; L-NAME group, ng/ml, IGF-1: 174.7 ± 19.3
vs. Saline, 276.0 ± 18.75, P < 0.01), consistentwith anormal negative
feed-back effect. IGF-1 increased bodyweight in both D- or L-NAME-
treated mice (Fig. 1B). L-NAME administration had no signiﬁcant
effect either on circulating IGF-1 levels or mouse body weight but
caused an elevation in blood pressure (BP) compared to D-NAME
controls. The L-NAME-induced BP increase reached statistical signif-
icance on the3rd, 4th and5thweeks and therewas a strong trend for
BP elevation in the L-NAMEgroups on the 7th, 8th and 10thweeks of
the experiment (Fig. 1C). This effect was consistent with prior re-
ports that NO deﬁciency elevated blood pressure in mouse models
[11,12]. We measured urinary nitrate/nitrite (NOx) (Fig. 1D), aFig. 1. Serum IGF-1 levels (A), body weight (B), blood pressure (C), and urinary nitrate
osmotic mini-pumps and fed aWestern-type diet for 12 weeks in presence of nitric oxide
every week and expressed as weight gain ratio (%) per body weight at day of pumps im
colorimetric assay followed by normalization to animal body weight. Data are shown
independent experiments (D).systemic index of NO bioavailability [13]. L-NAME administration
suppressed basal NOx levels by 30 ± 4% (Saline/L-NAME vs. Saline/
D-NAME, P < 0.01). IGF-1 increased NOx in the D-NAME group
(65 ± 8% increase vs. Saline, P < 0.01) after 8 weeks of infusion and
this effect was completely blunted by L-NAME administration. IGF-
1 also increased NOx levels in the D-NAME group (but not in
L-NAME-treated animals) after 4 and 12 weeks of infusion (data
not shown).
IGF-1 induced a weak ‘‘insulin-like’’ effect on blood glucose lev-
els. Glucose levels at 12 weeks were slightly reduced in IGF-1-
infused mice (D-NAME, mg/dL, IGF-1: 96 ± 24 vs. Saline: 146 ± 52,
P = NS; L-NAME, IGF-1:155 ± 37 vs. Saline: 200 ± 61, P = NS).
L-NAME induced a modest increase in blood glucose levels but this
effect was not statistically signiﬁcant. IGF-1 slightly reduced total
cholesterol levels (Supplementary Fig. 2) but this effect was not
statistically signiﬁcant, consistent with our previous report [9].
IGF-1 did not alter cholesterol content in serum VLDL, LDL and
HDL fractions (data not shown) and serum lipid proﬁles were not
affected either by IGF-1 or L-NAME as assessed by FPLC-based ser-
um lipoprotein fractionation (Supplementary Fig. 3).
3.2. L-NAME did not alter IGF-1’s effects on atherosclerotic plaque
burden, plaque composition and cell apoptosis
Atherosclerosis burden was measured by quantiﬁcation of sur-
face lesion area on Oil Red-stained whole aortas (en face analysis)
and also by measuring plaque size on H&E-stained aortic valves/nitrites (NOx) levels (D). Apoe-null mice were infused with saline or IGF-1 using
synthase inhibitor L-NAME or D-NAME (control). Mouse body weight were measured
plantation. IGF-1 levels were measured by ELISA (n = 8) and urinary NOx levels by
from representative experiment (A, B, C) and NOx data (D) combined from two
Fig. 2. IGF-1 reduced atherosclerotic lesion surface area on whole aortas (A and C) and decreased lesion size on aortic valve cross-sections (B and D) in L-NAME-treated mice
and, similarly, in control group. Apoe-null mice were infused with saline or IGF-1 and fed a Western-type diet in presence of L-NAME or D-NAME (control). Animals were
perfused/ﬁxed and hearts and aortas were dissected. Aortas were stain en face with Oil Red O (A) and hearts were parafﬁn-embedded and aortic valves cross-sections were
stained with H&E (B). Lesion surface area (C) or cross-sectional size (D) was quantiﬁed by manual outlining in Image Pro software. Data are shown from representative
experiment (n = 12).
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(en face: 37% decrease, aortic valve cross-sections: 10% decrease),
and this IGF-1-induced anti-atherogenic effect was not altered by
L-NAME (en face: 39.5% decrease, aortic valve cross-sections:
29% reduction) (Fig. 2) suggesting that NO does not mediate IGF-
1-induced reduction of atherosclerosis. L-NAME increased athero-
sclerotic burden of whole aortas by 65% (Saline/L-NAME vs. Saline/
D-NAME, P < 0.05) but L-NAME did not signiﬁcantly change aortic
valve atherosclerotic burden. We have shown previously that
SMC-speciﬁc IGF-1 overexpression increases plaque SMC and colla-
gen levels in Apoe/ mice suggesting that IGF-1 increased athero-
sclerotic plaque stability [14]. In the current study we determined
whether an increase in circulating IGF-1 also produced these effects
and whether they were NO-dependent. We found that plaque SMC
(a-SMA staining) were signiﬁcantly upregulated by IGF-1 in both D-
NAME- (2.05 ± 0.22-fold increase) and L-NAME-treated animals
(1.82 ± 0.21-fold increase) (Fig. 3A and B) indicating that NO did
not mediate the ability of IGF-1 to increase a-SMA expression.
IGF-1 increased the number of a-SMA/DAPI-double positive cells
in the atherosclerotic plaque and L-NAME did not change this effect
(D-NAME, Saline, 47.9 ± 11.9; IGF-1, 94.5 ± 17.3, P < 0.05; L-NAME,
Saline, 50.0 ± 10.9, IGF-1, 135.3 ± 2 2.3, P < 0.01). Interestingly,
IGF-1-treatedmice had only a trend to slightly increased plaque col-
lagen levels in both D-NAME and L-NAME groups (Fig. 3A and C) sug-
gesting that the increase in circulating IGF-1 was not sufﬁcient to
increase collagen, in contrast to the effect of SMC-speciﬁc IGF-1
overexpression [14].
Total plaque cell apoptosis was reduced by IGF-1 in both
D-NAME- and L-NAME-treated mice (37 ± 5% decrease compared to
saline, P < 0.05 and 30 ± 4% decrease, P < 0.05, respectively)
(Fig. 3D). Interestingly, IGF-1 had no effect on SMC cell apoptosis(data not shown) indicating that the anti-apoptotic effect of IGF-1
was exerted on non-SMC plaque cells.
3.3. Nitric oxide is required for IGF-1-induced anti-oxidant effects
Wehave shownpreviously that IGF-1 reduced superoxides in the
plaque-free aortic wall and suppressed systemic oxidative stress in
Apoe/ mice [9]. In the current study IGF-1-induced anti-oxidant
effects were assessed directly in the atherosclerotic plaque by
immunostaining with anti-8-oxo-D-guanosine (8-oxo-dG) and
anti-N-tyrosine (NT) antibodies (Fig. 4A), to measure oxidative
stress-induced DNA and protein modiﬁcation, respectively. Eight-
oxo-dG- and NT-immunopositivity was markedly stronger in the
atherosclerotic plaque region (especially, in the plaque cap)
compared to the adjacent aortic valve intima suggesting increased
oxidative stress in atherosclerotic plaque (data not shown). IGF-1
reduced 8-oxo-dG levels in the D-NAME group (51.8% decrease vs.
saline control, P < 0.01) and this effect was markedly blunted by L-
NAME (17.9% decrease, P = NS) (Fig. 4B). Similarly, IGF-1 reduced
the NT signal in D-NAME-treated mice (54.2% reduction vs. saline
control, P < 0.05) and this effect was also inhibited by L-NAME
(35% decrease, P = NS) (Fig. 4C). These data show that IGF-1-induced
reduction in oxidative stress is NO dependent.
3.4. Proﬁling of atherosclerosis-related molecules
To identify potential mediators of IGF-1-induced effects we
measured aortic gene expression of 86 atherosclerosis-related mol-
ecules using a PCR array (Supplementary Table 3). IGF-1 decreased
expression of the pro-atherogenicmoleculesmacrophage scavenger
receptor 1 (MSR-1/SR-A) (L-NAME group) and kinase insert domain
Fig. 3. IGF-1 increases plaque SMC content (A and B), suppresses cell apoptosis (A and D) and elevates collagen levels (A and C) in L-NAME-treated mice and, similarly, in
control group. Aortic valves cross-sections were stained with anti-a-smooth muscle actin (a-SMA) antibody to identify SMC or co-stain with anti-a-SMA antibody and TUNEL
stain to identify apoptotic cells and apoptotic SMC in the plaque. Gomori’s Trichrome stain was used to identify plaque collagen. a-SMA positive (B) or collagen (C) plaque
area was manually outlined in Image Pro and normalized per plaque area. Apoptotic cell number was normalized per total plaque cell number (D) or SMC number in the
plaque using DAPI. Representative images are shown for each group (n = 12).
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IGF-1 upregulated expression of the chemokine RANTES (CCL5) in
the L-NAMEgroup. IGF-1 decreased TNF-a expression and downreg-
ulated TNF-a-induced protein 3 mRNA levels in the D-NAME group
only. To conﬁrm this effect of IGF-1 on TNF-a expressionweperform
independent real-time PCR analysis of aortic TNF-a expression
(Fig. 5A). IGF-1markedly reduced aortic TNF-amRNA levels (consis-
tent with our previous report [9]) and this effect was blunted by
L-NAME. Furthermore, IGF-1 reduced circulating TNF-a levels (34%
decrease vs. saline), and this effect was also blunted by L-NAME
(Fig. 5B).Lipoprotein lipase (LPL) is a key pro-atherogenic enzyme [15]
secreted by macrophages in high levels [16] [17]. Our PCR arrays
indicated that IGF-1 reduced LPL expression in both D-NAME and
L-NAME groups (Supplementary Table). We conﬁrmed these
ﬁndings using independent real-time PCR and found that IGF-1
suppressed aortic LPL expression to a similar extent in the control
group (D-NAME) (46% decrease vs. saline, P < 0.05) and in mice
treated with L-NAME (59% decrease, P < 0.05) (Fig. 5C) indicating
that this effect was not dependent on nitric oxide.
We performed experiments with cultured human THP-1 macro-
phages to determine whether IGF-1 regulates TNF-a and LPL
Fig. 4. IGF-1 decreases oxidative stress in the atherosclerotic plaque and this effect is partially blocked by L-NAME. Aortic valves cross-sections were stained with anti-8-oxo-
dG antibody (A and B) to measure oxidative stress-induced DNA damage or with anti-N-tyrosine antibody (A and C) to quantify oxidative modiﬁcation of proteins.
Streptavidin-Alexa594 (red) (for 8-oxo-dG) or streptavidin-HRP/DAB (brown) (for N-tyrosine) signals have been quantiﬁed with Image Pro. Black arrows on N-tyrosine-
stained sections indicate strong positivity for this marker in plaque endothelial cells layer. Representative images are shown for each group (n = 6–8).
Fig. 5. IGF-1-induced reduction in TNF-a but not in lipoprotein lipase (LPL) is nitric oxide-dependent. Aortic TNF-a and LPL mRNA levels (A and C) were measured using real
time RT–PCR and serum TNF-a levels (B) with ELISA kit (n = 5).
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NO-dependent. IGF-1 downregulated TNF-a expression in macro-
phages (P < 0.05) and this effect was completely blocked by theNOS inhibitor (Fig. 6A). IGF-1 also reduced expression of LPL in
D-NAME-treated cells; however this effect was not altered by
L-NAME (Fig. 6B).
Fig. 6. IGF-1-induced reduction in macrophage-speciﬁc TNF-a but not in macrophage lipoprotein lipase (LPL) is nitric oxide-dependent. Human THP-1 cells were
differentiated into macrophages with phorbol 12-myristate 13-acetate and treated with serum-free media (SFM, control) or with 50 ng/ml human recombinant IGF-1 and
gene expression analysis was performed by quantative real-time RT–PCR. The experiment was repeated four times (n = 4 per group) and results of a representative
experiment are shown on the graph.
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In our ﬁrst report that IGF-1 reduced atherosclerosis in Apoe/
mice fed a Western diet [9] we had identiﬁed multiple potential
mechanisms, including an anti-oxidant effect of IGF-1 as evidenced
by reduced aortic superoxide and urinary 8-isoprostane levels, and
an increase in NO bioavailability, resulting perhaps in part from
IGF-1 induced increase in vascular eNOS expression and activation.
Recently we found that congenic 6T/Apoe/ mice with a 20%
decline in circulating IGF-1 had a signiﬁcant increase in atheroscle-
rotic burden and reduced vascular eNOS expression [18]. These
ﬁndings suggested that the ability of IGF-1 to increase NO bioavail-
ability could play an important role in the atheroprotective actions
of IGF-1. Indeed there is abundant data indicating that NO has ath-
eroprotective effects. NOS1-knockout mice exhibited accelerated
neointimal formation following carotid artery ligation [19], indi-
cating a vasculoprotective effect of neuronal NOS in vivo. On the
contrary, NOS2 deﬁciency resulted in reduced atherosclerosis in
Apoe/ mice [20] suggesting a pro-atherogenic role of this
enzyme. A deﬁciency of NOS3/eNOS accelerated atherosclerotic
lesion formation in Apoe/ mice [6] although in the setting of
hypercholesterolemia a depletion of BH4, an essential co-factor
for the enzyme, may lead to eNOS ‘‘uncoupling’’, superoxide pro-
duction and pro-atherogenic effects of eNOS [21,22]. The overall
contribution of all three NO synthases and the role of systemic
NO deﬁciency in atherosclerosis were elucidated by using triple
NOS/ mice which had increased blood pressure and markedly
elevated atherosclerosis burden following a high cholesterol diet,
consistent with a major anti-atherogenic role of nitric oxide [23].
Similar results were obtained using L-NAME to inhibit endogenous
NO [24]. Interestingly our current study indicates that although
L-NAME produced an expected increase in atherosclerotic plaque
burden (Fig. 2C) it did not abrogate the ability of IGF-1 to reduce
plaque burden indicating that the atheroprotective effect of IGF-1
was NO independent.
We reported recently that SMC-speciﬁc IGF-1 overexpression
increased features of atherosclerotic plaque stability [18], in partic-
ular, plaque SMC content and collagen expression. Our current data
indicates that IGF-1 infusion similarly increased plaque SMC con-
tent as demonstrated by an increase in a-SMA staining and in
the number of a-SMA/DAPI double-positive cells. Our ﬁnding is
consistent with a recent report that infusion of a stable IGF-1 ana-
logue in Apoe/ mice increased SMC content in the advanced pla-
que and reduced the rate of intra-plaque hemorrhage [25]. In
addition to increasing SMC content IGF-1 reduced plaque apoptosis
(Fig 3D). IGF-1 has been reported to prevent apoptosis in multiple
cell culture models including SMC [26], THP-1 macrophages [27]and cardiac myocytes [28]; however to our knowledge our current
ﬁndings are the ﬁrst to demonstrate that IGF-1 reduces total cell
apoptosis in vivo in the atherosclerotic plaque. Both the effects of
IGF-1 to increase SMC content and to reduce plaque apoptotic rate
were NO-independent suggesting that both could potentially con-
tribute to the anti-atherosclerotic effect of IGF-1. However it is per-
tinent to note that SMC-speciﬁc IGF-1 overexpression, while
markedly increasing the number of differentiated SMC, did not re-
duce total plaque burden [14], suggesting that the ability of infused
IGF-1 to reduce plaque burden is unlikely to be due mainly to the
increase in SMC content. Of note, contrary to the effects of IGF-1
overexpression in SMC, an increase in circulating IGF-1 did not sig-
niﬁcantly increase plaque collagen content (Fig 3).
We have shown previously that IGF-1 reduced superoxides in
the plaque-free aortic wall in Apoe/ mice on a Western diet
[9]. We now demonstrate that IGF-1 inhibits oxidative stress spe-
ciﬁcally in the atherosclerotic plaque. The IGF-1-induced antioxi-
dant effect was NO-dependent (at least in part) since the ability
of IGF-1 to reduce oxidative stress was signiﬁcantly blunted by
L-NAME (Fig. 4). This ﬁnding is consistent with the ability of IGF-
1 to upregulate eNOS expression and activity [29,30] leading to
increased NO levels in vivo and in vitro [31–33]. Contrary to its
anti-oxidant effect, IGF-1-induced suppression of atherosclerosis
was NO-independent. IGF-1 induced a similar reduction in athero-
sclerosis in L-NAME-treated mice compared to control indicating
that IGF-1’s anti-atherogenic effect does not depend on nitric
oxide. IGF-1-induced suppression of cell apoptosis and downregu-
lation of LPL were also NO-independent and as such could be
involved in the ability of IGF-1 to suppress atherosclerosis. Macro-
phage-speciﬁc LPL is known to increase binding of oxidized lipids
to macrophages thereby promoting formation of foam cells and
accelerating atherosclerosis in Apoe/ mice [34]. We found that
IGF-1 suppresses LPL expression in cultured macrophages and also
in atherosclerotic aortas and the latter effect correlated with de-
creased aortic lipid levels (measured by staining with Oil Red O).
Patients with growth hormone deﬁciency had reduced serum
IGF-1 levels and higher macrophage LPL expression and macro-
phages from these patients were more susceptible to foam cell for-
mation [35]. These data, taken together with our ﬁndings, suggest a
novel link between IGF-1, LPL downregulation and atherosclerosis
suppression.
In summary, we have demonstrated that IGF-1 increases NO lev-
els, suppresses plaque cell apoptosis and downregulates TNF-a in
Apoe-null mice, however NO is not required for IGF-1-induced
anti-atherogenic effects. IGF-1 reduces oxidative stress and
increasesSMClevels in theatheroscleroticplaqueandalsodownreg-
ulates LPL expression in vivo and in cultured macrophages. IGF-1
3072 S. Sukhanov et al. / FEBS Letters 585 (2011) 3065–3072downregulation of LPL is NO-independent and represents a novel
potential mechanismmediating IGF-1’s anti-atherosclerotic effects.
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